AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT)
9.305 USD
-0.105 1.116%Sponsored Reports
Loading...
| Previous Close (in USD) | 9.41 |
|---|---|
| Change | -0.105 1.116% |
| 52 W H/L (in USD) | 30.990/5.670 |
| EBITDA (in USD) | -84.972M |
| PE Ratio | -- |
| Volume | 262079 |
| Diluted Eps TTM | -1.80 |
| Total Assets (in USD) | 355.184M |
|---|---|
| Total Liabilities (in USD) | 88.861M |
| Revenue TTM (in USD) | 50.019M |
| Cash (in USD) | 281.263M |
| Market Cap (in USD) | 579.699 M |
| Revenue Per Share TTM | 1.170 |
| Gross Profit TTM (in USD) | 26.948M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Eyepoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Employees: 121
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Ms. Nancy S. Lurker | Pres, CEO & Director | 1957 |
| 2. | Mr. George O. Elston | Chief Financial Officer | 1965 |
| 3. | Dr. Jay S. Duker M.D. | Chief Operating Officer | 1959 |
| 4. | Mr. David Scott Jones | Sr. VP & Chief Commercial Officer | 1967 |
| 5. | Mr. Said Saim | Chief Technology Officer | 1958 |
| 6. | Mr. Ron I. Honig Esq. | Chief Legal Officer & Company Sec. | NA |
| 7. | Mr. Michael Pine | Chief Corp. Devel. & Strategy Officer | 1976 |
| 8. | Ms. Jennifer Leonard | Chief People Officer & Sr. VP of IT | NA |
| 9. | Dr. Dario A. Paggiarino | Sr. VP & Chief Medical Officer | 1957 |
| 10. | Ms. Isabelle Lefebvre | Chief Regulatory Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.580 0.840% | 68.41 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.450 0.659% | 70 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+7.745 1.740% | 445.5 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+12.918 2.461% | 523.97 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -70.712M | -102.254M | -58.417M | -45.394M | -56.793M |
| Minority Interest | - | - | - | - | - |
| Net Income | -70.795M | -124.512M | -63.915M | -52.651M | -62.969M |
| Selling General Administrative | 40.102M | 34.817M | 25.575M | 20.726M | 17.939M |
| Gross Profit | 41.386M | 33.078M | 28.762M | 28.613M | 17.678M |
| Reconciled Depreciation | 0.464M | 2.446M | 2.771M | 2.649M | 2.604M |
| Ebit | -73.662M | -78.938M | -55.276M | -37.29M | -47.861M |
| Ebitda | -73.198M | -74.757M | -52.524M | -34.772M | -44.347M |
| Depreciation And Amortization | 0.464M | 4.181M | 2.752M | 2.518M | 3.514M |
| Operating Income | -73.662M | -78.938M | -55.276M | -37.29M | -47.861M |
| Other Operating Expenses | 119.68M | 120.342M | 92.215M | 71.727M | 68.226M |
| Interest Expense | 1.247M | 3.189M | 5.498M | 7.257M | 6.176M |
| Tax Provision | 0.083M | 0M | - | - | - |
| Interest Income | 6.949M | 2.131M | 0.292M | 0.058M | 1.054M |
| Net Interest Income | 5.702M | -1.058M | -5.206M | -7.199M | -5.122M |
| Income Tax Expense | 0.083M | 22.258M | 5.498M | 7.257M | 6.176M |
| Total Revenue | 46.018M | 41.404M | 36.939M | 34.437M | 20.365M |
| Total Operating Expenses | 115.048M | 112.016M | 84.038M | 65.903M | 65.539M |
| Cost Of Revenue | 4.632M | 8.326M | 8.177M | 5.824M | 2.687M |
| Total Other Income Expense Net | 2.95M | -23.316M | -3.141M | -8.104M | -8.932M |
| Net Income From Continuing Ops | -70.795M | -102.254M | -58.417M | -45.394M | -56.793M |
| Net Income Applicable To Common Shares | - | -102.254M | -58.417M | -45.394M | -56.793M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 355.184M | 180.356M | 263.372M | 91.717M | 73.323M |
| Intangible Assets | - | - | 22.749M | 25.209M | 27.669M |
| Other Current Assets | 9.039M | 9.858M | 4.217M | 3.419M | 8.135M |
| Total Liab | 88.861M | 83.988M | 78.992M | 73.176M | 64.993M |
| Total Stockholder Equity | 266.323M | 96.368M | 184.38M | 18.541M | 8.33M |
| Other Current Liab | 17.604M | 16.938M | 14.422M | 0.687M | 6.832M |
| Common Stock | 0.049M | 766.933M | 752.636M | 528.38M | 472.776M |
| Capital Stock | 0.049M | 0.034M | 0.034M | 0.018M | 0.109M |
| Retained Earnings | -742.146M | -671.351M | -569.097M | -510.68M | -465.286M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.15M | 0.626M | 0.15M | 0.15M |
| Cash | 281.263M | 95.633M | 178.593M | 44.909M | 22.214M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 63.263M | 34.537M | 23.658M | 14.888M | 11.872M |
| Current Deferred Revenue | 38.592M | 1.205M | 1.069M | 0.945M | 0.015M |
| Net Debt | -275.794M | -49.864M | -140.171M | -4.602M | 28.388M |
| Short Term Debt | 0.563M | 10.475M | 0.782M | 8.445M | 0.481M |
| Short Long Term Debt | - | 10.475M | - | - | - |
| Short Long Term Debt Total | 5.469M | 45.769M | 38.422M | 40.307M | 50.602M |
| Other Stockholder Equity | 1007.556M | 766.899M | 752.602M | 528.362M | 472.667M |
| Property Plant Equipment | - | 1.36M | 2.252M | 0.63M | 0.357M |
| Total Current Assets | 344.8M | 172.808M | 237.745M | 63.118M | 42.069M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 49.787M | 48.928M | 32.965M | - | - |
| Net Receivables | 0.805M | 15.503M | 18.354M | 9.453M | 11.72M |
| Long Term Debt | - | 29.31M | 36.562M | 37.977M | 47.223M |
| Inventory | 3.906M | 2.886M | 3.616M | 5.337M | 2.138M |
| Accounts Payable | 6.504M | 5.919M | 7.385M | 4.811M | 11.376M |
| Accumulated Other Comprehensive Income | 0.864M | 0.786M | 0.841M | 0.841M | 0.84M |
| Non Currrent Assets Other | 0.15M | 1.51M | 0.626M | 0.15M | 0.507M |
| Non Current Assets Total | 10.384M | 7.548M | 25.627M | 28.599M | 31.254M |
| Capital Lease Obligations | 4.906M | 6.563M | 2.642M | 2.33M | 3.379M |
| Long Term Debt Total | - | 29.31M | 36.562M | 37.977M | 47.223M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | -3.315M | -15.115M | -32.965M | -0.362M | -0.213M |
| Total Cashflows From Investing Activities | - | -17.265M | -33.121M | -0.362M | -0.213M |
| Total Cash From Financing Activities | 187.07M | -0.69M | 216.902M | 37.492M | 33.864M |
| Net Income | -70.795M | -102.254M | -58.417M | -45.394M | -56.793M |
| Change In Cash | 185.63M | -82.96M | 133.684M | 22.695M | -23.047M |
| Begin Period Cash Flow | 95.633M | 178.743M | 45.059M | 22.364M | 45.411M |
| End Period Cash Flow | 281.263M | 95.783M | 178.743M | 45.059M | 22.364M |
| Total Cash From Operating Activities | 1.875M | -65.005M | -50.097M | -14.435M | -56.699M |
| Depreciation | 0.464M | 2.446M | 2.771M | 2.649M | 2.604M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -1.553M | -0.76M | 1.347M | -3.2M | -1.859M |
| Sale Purchase Of Stock | -0.169M | -0.295M | -0.15M | -0.09M | -0.12M |
| Other Cashflows From Financing Activities | -1.97M | 7.977M | 0.223M | 1.417M | 31.237M |
| Capital Expenditures | 3.483M | 2.15M | 0.156M | 0.362M | 0.213M |
| Change In Working Capital | 58.882M | -3.023M | -1.739M | 20.136M | -12.536M |
| Other Non Cash Items | 1.184M | 23.649M | 0.628M | 1.722M | 1.648M |
| Free Cash Flow | -1.608M | -67.155M | -50.253M | -14.797M | -56.912M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Franklin Biotechnology Discv A(acc)USD | 1 year ago | 1543363 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 1487245 |
| 3. | T. Rowe Price New Horizons | 1 year ago | 1218598 |
| 4. | US Small-Cap Growth II Equity Comp | 1 year ago | 1218598 |
| 5. | Franklin Small Cap Growth Adv | 1 year ago | 1192700 |
| 6. | Franklin Small Cap Growth SMA | 1 year ago | 1192700 |
| 7. | Franklin US Small Cap Growth Equity | 1 year ago | 1192700 |
| 8. | iShares Russell 2000 ETF | 1 year ago | 873512 |
| 9. | Franklin Biotechnology Discovery A | 1 year ago | 830629 |
| 10. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 552024 |
| 11. | Columbia Small Cap Growth Inst | 1 year ago | 441993 |
| 12. | Columbia Small Cap Growth | 1 year ago | 441993 |
| 13. | T. Rowe Price Small-Cap Value | 1 year ago | 412911 |
| 14. | Candriam Eqs L Biotech C USD Cap | 1 year ago | 383000 |
| 15. | Federated Hermes MDT SCC Institutional | 1 year ago | 367841 |
| 16. | Federated Hermes MDT Small Cap Core IS | 1 year ago | 367841 |
| 17. | T. Rowe Price US Small-Cap Core Equity | 1 year ago | 367572 |
| 18. | T. Rowe Price Small-Cap Stock | 1 year ago | 367572 |
| 19. | Fiera SMID Growth | 1 year ago | 303460 |
| 20. | Fidelity Small Cap Index | 1 year ago | 272941 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Cormorant Asset Management, LLC | 1 year ago | 6893235 |
| 2. | Adage Capital Partners Gp LLC | 1 year ago | 4756299 |
| 3. | Franklin Resources Inc | 1 year ago | 4640651 |
| 4. | Suvretta Capital Management, LLC | 1 year ago | 3763888 |
| 5. | T. Rowe Price Associates, Inc. | 1 year ago | 2465815 |
| 6. | Vanguard Group Inc | 1 year ago | 2396228 |
| 7. | BlackRock Inc | 1 year ago | 2169306 |
| 8. | Millennium Management LLC | 1 year ago | 2046438 |
| 9. | T. Rowe Price Investment Management,Inc. | 1 year ago | 1604763 |
| 10. | Essex Woodlands Health Ventures | 1 year ago | 1551521 |
| 11. | Ameriprise Financial Inc | 1 year ago | 1536125 |
| 12. | Morgan Stanley - Brokerage Accounts | 1 year ago | 1318897 |
| 13. | Goldman Sachs Group Inc | 1 year ago | 1135972 |
| 14. | Octagon Capital Advisors LP | 1 year ago | 1093503 |
| 15. | Deutsche Bank AG | 1 year ago | 770503 |
| 16. | Geode Capital Management, LLC | 1 year ago | 682417 |
| 17. | Fiera Capital Corporation | 1 year ago | 671118 |
| 18. | Finepoint Capital LP | 1 year ago | 656600 |
| 19. | Federated Hermes Inc | 1 year ago | 643176 |
| 20. | LAURION CAPITAL MANAGEMENT LP | 1 year ago | 629396 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...